PIKE mediates EGFR proliferative signaling in squamous cell carcinoma cells

Oncogene

Volumn 31, Issue 49, 2012, Pages 5090-5098

  Xie, Z ^a,b   Jiang, Y ^a   Liao, E Y ^a   Chen, Y ^c   Pennypacker, S D ^b   Peng, J ^a   Chang, S M ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

EGFR; PIKE; PLC g1; proliferation; SCC

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NUCLEOLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ENHANCER; PHOSPHOLIPASE C GAMMA1; PHOSPHOTRANSFERASE; PROTEIN KINASE C ZETA; UNCLASSIFIED DRUG;

ARTICLE; CANCER TISSUE; CARCINOMA CELL; CATALYSIS; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; EPIDERMIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MEDIATOR; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN EPITHELIUM; SQUAMOUS CELL CARCINOMA; STAINING; TONGUE; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; GENE KNOCKDOWN TECHNIQUES; GTP-BINDING PROTEINS; GTPASE-ACTIVATING PROTEINS; HUMANS; KERATINOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOLIPASE C GAMMA; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE C; RECEPTOR, EPIDERMAL GROWTH FACTOR; REFERENCE VALUES; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; TONGUE NEOPLASMS;

EID: 84870853914     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.10     Document Type: Article

References (52)

1. Hiraishi Y, Wada T, Nakatani K, Negoro K, Fujita S. Immunohistochemicalexpression of EGFR and p-EGFR in oral squamous cell carcinomas. Pathol OncolRes 2006; 12: 87-91.
2. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N et al. EGFR proteinoverexpression and gene amplification in squamous cell carcinomas of theesophagus. Int J Cancer 2006; 118: 1173-1180.
3. Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O.Overexpression of EGFR and absence of C-KIT expression correlate with poorprognosis in salivary gland carcinomas. Histopathology 2008; 53: 567-577.
4. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas:prognostic significance of protein overexpression and high gene copy number.Histopathology 2008; 52: 738-746.
5. Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P et al. EGFRoverexpression in malignant pleural mesothelioma. An immunohistochemical andmolecular study with clinico-pathological correlations. Lung Cancer 2006; 51:207-215.
6. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG et al.Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroidcancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroidcancer. Clin Cancer Res 2004; 10: 8594-8602.
7. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA. EGFR expression andHER2/neu overexpression/amplification in endometrial carcinosarcoma. GynecolOncol 2006; 100: 101-106.
8. Rakosy Z, Vizkeleti L, Ecsedi S, Voko Z, Begany A, Barok M et al. EGFR gene copynumber alterations in primary cutaneous malignant melanomas are associatedwith poor prognosis. Int J Cancer 2007; 121: 1729-1737.
9. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V et al. Epidermalgrowth factor receptor (EGFR) expression is associated with a worse prognosisin gastric cancer patients undergoing curative surgery. World J Surg 2007; 31:1458-1468.
10. Zlobec I, Vuong T, Hayashi S, Haegert D, Tornillo L, Terracciano L et al. A simpleand reproducible scoring system for EGFR in colorectal cancer: application toprognosis and prediction of response to preoperative brachytherapy. Br J Cancer2007; 96: 793-800.
11. Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R et al. Impact ofEGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol2005; 16: 102-108.
12. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009; 77: 400-410.
13. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target incancer therapy: understanding the role of receptor expression and othermolecular determinants that could influence the response to anti-EGFR drugs.Eur J Cancer 2003; 39: 1348-1354.
14. Speake G, Holloway B, Costello G. Recent developments related to the EGFR as atarget for cancer chemotherapy. Curr Opin Pharmacol 2005; 5: 343-349.
15. Harris RC, Chuang E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003; 284:2-13.
16. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-643.
17. Rotin D, Honegger AM, Margolis BL, Ullrich A, Schlessinger J. Presence of SH2domains of phospholipase C-c1 enhances substrate phosphorylation byincreasing the affinity toward the epidermal growth factor receptor. J Biol Chem1992; 267: 9678-9683.
18. Kim MJ, Kim E, Ryu SH, Suh PG. The mechanism of phospholipase C-c1 regulation.Exp Mol Med 2000; 32: 101-109.
19. Falasca M, Logan SK, Lehto VP, Baccante G, Lemmon MA, Schlessinger J.Activation of phospholipase C c by PI 3-kinase-induced PH domain- mediatedmembrane targeting. EMBO J 1998; 17: 414-422.
20. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H et al. Proteinkinase C-a activates RAF-1 by direct phosphorylation. Nature 1993; 364: 249-252.
21. Carroll MP, May WS. Protein kinase C-mediated serine phosphorylation directlyactivates Raf-1 in murine. J Biol Chem 1994; 269: 1249-1256.
22. Cacace AM, Ueffing M, Philipp A, Han EK, Kolch W, Weinstein IB. PKC-e functionsas an oncogene by enhancing activation of the Raf kinase. Oncogene 1996; 13:2517-2526.
23. Zou Y, Komuro I, Yamazaki T, Aikawa R, Kudoh S, Shiojima I et al. Protein kinase C,but not tyrosine kinases or Ras, plays a critical role in angiotensin II-inducedactivation of Raf-1 kinase and extracellular signal-regulated protein kinases incardiac myocytes. J Biol Chem 1996; 271: 33592-33597.
24. Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, Ohno S. Protein kinase C activatesthe MEK-ERK pathway in a manner independent of Ras and dependent on Raf.J Biol Chem 1996; 271: 23512-23519.
25. Cai H, Smola U, Wixler V, Eisenmann-Tappe I, Diaz-Meco MT, Moscat J et al. Role ofdiacylglycerol-regulated protein kinase C isotypes in growth factor activation ofthe Raf-1 protein kinase. Mol Cell Biol 1997; 17: 732-741.
26. Ji QS, Ermini S, Baulida J, Sun FL, Carpenter G. Epidermal growth factor signalingand mitogenesis in Plcg1 null mouse embryonic fibroblasts. Mol Biol Cell 1998; 9:749-757.
27. Chen P, Xie H, Sekar MC, Gupta K, Wells A. Epidermal growth factor receptormediatedcell motility: phospholipase C activity is required, but mitogen-activatedprotein kinase activity is not sufficient for induced cell movement. J Cell Biol 1994;127: 847-857.
28. Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J et al. Epidermalgrowth factor receptor-stimulated activation of phospholipase C-c1 promotesinvasion of head and neck squamous cell carcinoma. Cancer Res 2003; 63:5629-5635.
29. Smith MR, Liu YL, Kim SR, Bae YS, Kim CG, Kwon KS et al. PLC-c1 Src homologydomain induces mitogenesis in quiescent NIH 3T3 fibroblasts. Biochem BiophysRes Commun 1996; 222: 186-193.
30. Huang PS, Davis L, Huber H, Goodhart PJ, Wegrzyn RE, Oliff A et al. An SH3domain is required for the mitogenic activity of microinjected phospholipaseC-c1. FEBS Lett 1995; 358: 287-292.
31. Wang Z, Gluck S, Zhang L, Moran MF. Requirement for phospholipase C-c1enzymatic activity in growth factor-induced mitogenesis. Mol Cell Biol 1998; 18:590-597.
32. Xie Z, Chen Y, Liao EY, Jiang Y, Liu FY, Pennypacker SD. Phospholipase C-c1 isrequired for the epidermal growth factor receptor-induced squamous cellcarcinoma cell mitogenesis. Biochem Biophys Res Commun 2010; 397: 296-300.
33. Xie Z, Chen Y, Pennypacker SD, Zhou Z, Peng D. The SH3 domain, but not thecatalytic domain, is required for phospholipase C-c1 to mediate epidermalgrowth factor-induced mitogenesis. Biochem Biophys Res Commun 2010; 398:719-722.
34. Ye K, Aghdasi B, Luo HR, Moriarity JL, Wu FY, Hong JJ et al. Phospholipase C-c1 is aphysiological guanine nucleotide exchange factor for the nuclear GTPase PIKE.Nature 2002; 415: 541-544.
35. Ye K, Hurt KJ, Wu FY, Fang M, Luo HR, Hong JJ et al. PIKE: A Nuclear GTPase thatEnhances PI3Kinase Activity and Is Regulated by Protein 4.1N. Cell 2000; 103:919-930.
36. Toker A, Meyer M, Reddy KK, Falck JR, Aneja R, Aneja S et al. Activation of proteinkinase C family members by the novel polyphosphoinositides PtdIns-3,4-P2 andPtdIns-3,4,5-P3. J Biol Chem 1994; 269: 32358-32367.
37. Carpenter G, Ji Q. Phospholipase C-c as a signal-transducing element. Exp Cell Res1999; 253: 15-24.
38. Zhou G, Seibenhener ML, Wooten MW. Nucleolin is a protein kinase C-f substrate.Connection between cell surface signaling and nucleus in PC12 cells. J Biol Chem1997; 272: 31130-31137.
39. Ginisty H, Sicard H, Roger B, Bouvet P. Structure and function of nucleolin. J CellSci 1999; 112: 761-772.
40. Tuteja R, Tuteja N. Nucleolin: a multifunctional major nucleolar phosphoprotein.Crit Rev Eukaryot Gene Expr 1998; 33: 407-436.
41. Srivastava M, Pollard HB. Molecular dissection of nucleolin's role in growth andcell proliferation: new insights. FASEB J 1999; 13: 1911-1922.
42. Ahn J-Y, Hu Y, Kroll TG, Allard P, Ye K. PIKE-A is amplified in human cancersand prevents apoptosis by up-regulating Akt. Proc Natl Acad Sci USA 2004; 101:6993-6998.
43. Liu X, Hu Y, Hao C, Rempel SA, Ye K. PIKE-A is a proto-oncogene promoting cellgrowth, transformation and invasion. Oncogene 2007; 26: 4918-4927.
44. Mizukami Y, Hirata T, Yoshida K. Nuclear translocation of PKC-f during ischemiaand its inhibition by wortmannin, an inhibitor of phosphatidylinositol 3-kinase.FEBS Lett 1997; 401: 247-251.
45. Neri LM, Martelli AM, Borgatti P, Colamussi ML, Marchisio M, Capitani S. Increase innuclear phosphatidylinositol 3-kinase activity and phosphatidylinositol (3,4,5)trisphosphate synthesis precede PKC-f translocation to the nucleus of NGFtreatedPC12 cells. FASEB J 1999; 13: 2299-2310.
46. Calcerrada MC, Miguel BG, Martin L, Catalan RE, Martinez AM. Involvementof phosphatidylinositol 3-kinase in nuclear translocation of proteinkinase C-f induced by C2-ceramide in rat hepatocytes. FEBS Lett 2002; 514:361-365.
47. Tajrishi MM, Tuteja R, Tuteja N. Nucleolin: The most abundant multifunctionalphosphoprotein of nucleolus. Commun Integr Biol 2011; 4: 267-275.
48. Storck S, Thiry M, Bouvet P. Conditional knockout of nucleolin in DT40 cellsreveals the functional redundancy of its RNA-binding domains. Biol Cell 2009; 101:153-167.
49. Pillai S, Bikle DD, Hincenbergs M, Elias PM. Biochemical and morphologicalcharacterization of growth and differentiation of normal human neonatalkeratinocytes in a serum-free medium. J Cell Physiol 1988; 134: 229-237.
50. Xie Z, Bikle DD. The recruitment of phosphatidylinositol 3-kinase to theE-cadherin-catenin complex at the plasma membrane is required for calciuminducedphospholipase C-c1 activation and human keratinocyte differentiation.J Biol Chem 2007; 282: 8695-8703.
51. Xie Z, Chang SM, Pennypacker SD, Liao EY, Bikle DD. Phosphatidylinositol- 4-phosphate 5-kinase 1a mediates extracellular calcium-induced keratinocytedifferentiation. Mol Biol Cell 2009; 20: 1695-1704.
52. Xie Z, Singleton PA, Bourguignon LY, Bikle DD. Calcium-induced human keratinocytedifferentiation requires src-and fyn-mediated phosphatidylinositol 3-kinasedependentactivation of phospholipase C-c1. Mol Biol Cell 2005; 16: 3236-3246.